CAS: 373384-18-0; (3-(Methylsulfonyl)Phenyl)Boronic Acid

该化合物是一种多用途碳酸衍生物,广泛用于Suzuki-Miyaura交叉组合反应,这是有机合成中形成碳-碳联系的关键方法.在元位置的甲烷硫基(mesyl)组加强了化合物的回活动性和稳定性,使其在制药和材料科学应用中特别宝贵.它的高度纯度和一贯性能确保了催化变异的可靠结果.该化合物也与一系列功能组相容,在复杂的分子构造中提供了灵活性.建议在惰性条件下进行适当的处理以保持其完整性.该试剂是需要精确和高效的丙烯联动的研究人员的首选.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号346688-57-1 Piperazine, 1-[... | CAS号1221265-37-7 3-Methyl-2-[3'-...

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-10308615-B2
    优先权日:2015-05-29
    标 题:Heterocyclic compounds as inhibitors of Vanin-1 enzyme
    发明人:CASIMIRO-GARCIA AGUSTIN; CONDON JEFFREY SCOTT; FLICK ANDREW CHRISTOPHER; GOPALSAMY ARIAMALA; KIRINCICH STEVEN J; MATHIAS JOHN PAUL; STROBACH JOSEPH WALTER; XIANG JASON SHAOYUN; XING LI HUANG; WANG XIAOLUN
    权利人:PFIZER
    摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-9938258-B2
    优先权日:2012-11-29
    标 题:Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
    发明人:BALOGLU ERKAN; SHECHTER SHARON; SHACHAM SHARON; MCCAULEY DILARA; SENAPEDIS WILLIAM; GOLAN GALI; KALID ORI
    权利人:KARYOPHARM THERAPEUTICS INC
    摘要:The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula I: n nor a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

    专利号:US-2009137557-A1
    优先权日:2005-11-22
    标题 :Calcilytic Compounds
    发明人:KU THOMAS WEN FU; LIN HONG; LUENGO JUAN I; MARQUIS JR ROBERT W; RAMANJULU JOSHI M; TROUT ROBERT; YAMASHITA DENNIS S
    权利人:KU THOMAS WEN FU; LIN HONG; LUENGO JUAN I; MARQUIS JR ROBERT W; RAMANJULU JOSHI M; TROUT ROBERT; YAMASHITA DENNIS S
    摘要:Novel calcilytic compounds, pharmaceutical compositions, methods of synthesis and methods of using them are provided.

    专利号:US-2007275968-A1
    优先权日:2004-09-07
    标 题 :Substituted Biphenyl Derivative
    发明人:KURATA HITOSHI; NISHIMATA TOYOKI; WATANABE YUKIKO; EBISAWA MASAYUKI; FUJIMOTO TEPPEI; KOBAYASHI HIDEKI
    权利人:KURATA HITOSHI; NISHIMATA TOYOKI; WATANABE YUKIKO; EBISAWA MASAYUKI; FUJIMOTO TEPPEI; KOBAYASHI HIDEKI
    摘要:The present invention relates to a biaryl derivative or a pharmacologically acceptable salt thereof having an excellent collagen-synthesis inhibition activity. A biaryl derivative having a structure represented by the following General Formula (I) or a pharmacologically acceptable salt thereof: n nwherein n R 1 represents a C 6 -C 10 aryl group which is substituted with one to three group(s) each independently selected from the group consisting of a group defined by formula R-L-, a di-(C 1 -C 6 alkyl)amino group, a di-(C 1 -C 6 alkyl)aminosulfonyl group, a hydroxyaminocarbonyl group, and a halogen atom, and so on; R represents a C 1 -C 6 alkyl group, and so on; L represents a sulfonyl group, an aminosulfonyl group, or a sulfonylamino group, and so on; R 2 represents a hydrogen atom, and so on; A represents a group defined by formula (II), (III), or (IV); R 3 represents a C 1 -C 6 alkyl group, and so on; and R 4 represents a C 1 -C 6 alkyl group, and so on.

    专利号:US-9834551-B2
    优先权日:2013-04-18
    标 题 :Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors
    发明人:VANKAYALAPATI HARIPRASAD; YERRAMREDDY VENKATAKRISHNAREDDY; GANGIREDDY PARAMAREDDY; APPALANENI RAJENDRA P
    权利人:ARRIEN PHARMACEUTICALS LLC
    摘要:The present invention relates to compounds described by Formula I: n nsalts thereof, their synthesis, and their use as ITK and JAK3 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such disease associated with abnormal cell growth such as autoimmune, inflammation, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, ulcerative colitis, psoriatic arthritis, psoriasis, Crohn's, metabolic and cancer diseases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions and processes for preparing the compounds of the invention.
    天津安浩生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.ahpharmatech.com
    企业联系电话:022-84840027👤
    📞天津安浩生物科技有限公司 ⚠️参考联系方式
    联系人:马经理
    电话:022-84840027

    传真:022-84840027
    邮箱:sales@ahpharmatech.com
    通信地址: 天津市东丽区四纬路10号2-201
    邮编: 300300
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:天津市东丽区四纬路10号2-201
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    北京普瑞东方化学技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.bjpurechem.com
    企业联系电话:010-83993285👤
    📞北京普瑞东方化学技术有限公司 ⚠️参考联系方式
    联系人:冷先生
    电话:010-83993285
    手机:17610176018
    传真:010-63370219
    邮箱:sales@bjpurechem.com
    通信地址: 北京市海淀区西三环北路50号院6号楼豪柏大厦1708室
    邮编: 100048
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:北京市海淀区西三环北路50号院6号楼豪柏大厦1708室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:Migliorini, F.; Puglioli, S.; Neri, D.; Cazzamalli, S.; Favalli, N., Science of Synthesis: DNA-Encoded Libraries, (2024) nan, 111.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知